Abstract:
The present invention relates to the use of 3,7-diazabicyclo[3,3,1]nonane compounds, preferably of 9,9-alkylene-3,7diazabicyclo[3,3,1]nonane compounds, and most preferably to the use of tedisamil, and the physiologically acceptable acid addition salts and/or solvates thereof, in the form of a liquid pharmaceutical preparation for the treatment and/or prophylaxis of anti-arrhythmic events in human patients, preferably in conversion of recent onset of atrial fibrillation (Afib) or flutter to normal sinus rhythm (NSR) in human patients. Furthermore, the invention relates to method of treatments and to pharmaceutical products.
Abstract:
The present invention relates to the use of 3,7-diazabicyclo[3,3,1]nonane compounds, preferably of 9,9-alkylene-3,7-diazabicyclo[3,3,1]nonane compounds, and most preferably to the use of tedisamil, and the physiologically acceptable acid addition salts and/or solvates thereof, in the form of a liquid pharmaceutical preparation for the treatment and/or inhibition of anti-arrhythmic events in human patients, preferably in conversion of recent onset of atrial fibrillation or flutter to normal sinus rhythm in humans. Furthermore, the invention concerns related methods of treatment and pharmaceutical products.
Abstract:
Se describe una nueva politerapia para enfermedades o dolencias cardiovasculares, administrando una combinacion sinergica de por lo menos un inhibidor de endopeptidasa neutra, por lo menos un inhibidor del sistema productor de endotelina endogena y por lo menos un diuretico, preferentemente un diuretico de tiazida o un antagonista del receptor A1 de adenosina.
Abstract:
Una nueva terapia de combinacion se describe para enfermedades cardiovasculares, en particular hipertension esencial, hipertension pulmonar y/o insuficiencia cardíaca congestiva, administrando una combinacion sinérgica de, al menos un inhibidor de endopeptidasa neutra, al menos un inhibidor del sistema productor de endotelina endogena y, al menos un antagonista el receptor AT1. Kit que comprende dicha terapia.
Abstract:
A combination therapy is disclosed for treating or inhibiting cardiovascular or metabolic diseases or conditions through a combination of at least one inhibitor of neutral endopeptidase (=NEP), at least one inhibitor of the endogenous endothelin producing system and at least one HMG CoA reductase inhibitor. Pharmaceutical compositions are also described comprising NEP inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors and the use of these pharmaceutical composition in the prophylaxis or treatment of cardiovascular and/or metabolic disorders or diseases in mammals (including humans).